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Primary cutaneous follicle center lymphoma (PCFCL) is characterized by a proliferation of follicle center cells in the skin. A
deﬁnitive diagnosis is frequently delayed because of diﬃculties in interpretation of the histopathologic ﬁndings. It has an excellent
prognosis with a 5-year survival over 95% and its risk of transformation has not been established. We describe a case report of
man with a gastric diﬀuse large B-cell lymphoma (DLBCL) referred to our clinic because of nodules in the back that had gradually
developed over a period of 10 years. A biopsy performed 3 years before was interpreted as reactive follicular hyperplasia. A new
skin biopsy revealed a diﬀuse large B-cell lymphoma and immunoglobulin heavy chain gene rearrangements from the initial skin
biopsy (PCBCL) and the DLBCL gastric biopsy were studied by polymerase chain reaction and an identical clonal rearrangement
was detected which was highly suggestive of a transformation lymphoma.
1.CaseReport
Primary cutaneous follicle center lymphoma (PCFCL) is
characterized by a proliferation of follicle center cells (cen-
trocytes and centroblasts) with a follicular, follicular and
diﬀuse, or diﬀuse growth pattern [1]. It shows a predilection
for the scalp, forehead, and trunk and dissemination to
extracutaneous sites rarely occurs [2]. Transformation of
systemic follicular lymphoma (FL) into aggressive non-
Hodgkin
,s Lymphoma is associated with poor prognosis and
has been reported with a wide range of frequency (range
between10%–70%).Whiletheannualriskoftransformation
of systemic FL is 3%, PCFCL has an excellent prognosis with
a5 - y e a rs u r v i v a lo v e r9 5 %[ 1] and its risk of transformation
has not been established [3].
We describe a case report of a 44-year-old white man
with a gastric diﬀuse large B-cell lymphoma (DLBCL)
referred to our clinic by the hematology department because
of multiple erythematous to purple, sharply demarcated
pruritic nodules in the back that enlarged and coalesced
in the previous year originating a tumor measuring 11 ×
7cm in diameter (Figure 1). These lesions had gradually
developed over a period of 10 years and a biopsy of one of
the nodules was diagnosed in a diﬀerent hospital as reactive
follicular hyperplasia. These ﬁndings were interpreted as an
inﬂammatory pseudolymphomatous reaction. He received
treatment with tetracyclines and had improvement after sun
exposure.
Recently,hewasreferredforanupperendoscopybecause
of epigastric pain and weight loss. Endoscopy revealed two
gastric ulcers (H. Pylori positive) (Figure 2)a n dac o m p u t e r
tomography showed both mural thickening of the gastric
mucosa and mediastinal and axilar lymphadenopathy. A
gastric biopsy revealed a DLBCL (Figures 3(a)–3(d)). A bone
marrow aspirate and biopsy showed minimal inﬁltration
by low-grade B-cell lymphoma. A new biopsy of the skin2 Case Reports in Medicine
Figure 1: Multiple erythematous to purple, sharply demarcated pruritic nodules in the back that enlarged and coalesced in the last year
originating a tumor measuring 11 ×7cm in diameter with some satellite lesions.
Figure 2: Endoscopy revealed two gastric ulcers. Biopsy revealed a DLBCL.
(a) (b)
(c) (d)
Figure 3: Stomach biopsy: (a) H&EX40 (Olympus BX40)—DLBCL, (b) antibody staining CD 20+, (c) antibody staining BCL6+, (d)
antibody staining Ki67+.Case Reports in Medicine 3
Figure 4: Skin biopsy 2009: H&EX40 (Olympus BX40) —DLBCL.
(a) (b)
(c) (d)
Figure 5: Skin biopsy 2006: (a) H&EX40 (Olympus BX40)—Primary cutaneous follicle center lymphoma, (b) antibody staining CD 20+,
(c) antibody staining BCL6+, (d) antibody staining Ki67+.
lesions was performed and demonstrated diﬀuse inﬁltrate of
conﬂuent sheets of centroblasts, with many mitotic ﬁgures.
The cells were CD20+, CD3−, CD30−, and BCL6+ and had
a high proliferation rate (Ki67+), features compatible with
DLBCL (Figure 4). The peripheral blood analysis revealed:
normal beta-2-microglobulin (1,70mg/L) and elevated LHD
(571U/L) levels. The lymphoma classiﬁcation was DLBCL
stage IV A; International Prognostic Index (IPI): 2.
On re-examination, the skin biopsy obtained 3 years ear-
lierwasBCL2weaklypositive,CD10negative,CD20positive,
and BCL6 positive and was reclassiﬁed as PCFCL (Figure 5).
Immunoglobulin heavy chain gene (IgH) rearrangements
were studied by polymerase chain reaction (PCR) using the
Biomed2 strategy [4] in the earlier PCFCL and in the subse-
quent DLBCL biopsies of the skin and stomach, respectively.
In each biopsy an identical clonal VH-JH rearrangement was
detected using FR1 and FR2 primers: 328 base pairs (bps)
and 258bps, respectively (Figures 6(a)–6(b)).
The patient received six cycles of rituximab, cyclophos-
phamide,adriamycin,vincristineandprednisone(R-CHOP)
chemotherapy, and omeprazole (20mg once a day), with
no improvement. Afterwards, he had undergone three
diﬀerent chemotherapy regimens (R-ESHAP, GEMROX, and
IFM/VP16) with no response.
2. Discussion
PCFCL morphologic and phenotypic features can be similar
or identical to those observed in secondary cutaneous
involvement by systemic FL [5]. In our patient we cannot
aﬃrmwithcertaintythattheinitiallesionwasaPCFCLsince4 Case Reports in Medicine
90 120 150 180 210 240 270 300 330 360 390
420
210
0
7040
5280
3520
1760
0
1120
560
0
6B: A4• 14314-FR1+FR3/ 6B: A4• 14314-FR1+FR3/
10B: A8• 14316-FR1+FR3/ 10R: A8• 14316-FR1+FR3/
13B: A11• TONSIL-FR1+FR3/ 13R: A11• TONSIL-FR1+FR3/
Skin biopsy 2006
328 base pair monoclonal product
Gastric biopsy 2009
Policlonal (tonsil) control
(a)
80 100 120 140 160 180 200 220 240 260 270 300
400
0
1800
900
0
200
0
20B: B4• 14314-FR2/ 20B: B4• 14314-FR2/
24B: B8• 14316-FR2/ 24R: B8• 14316-FR2/
43B: D2• TONSIL-FR2/ 43R: D2• TONSIL-FR2/
Skin biopsy 2006
258 base pair monoclonal product
Gastric biopsy 2009
Policlonal (tonsil) control
(b)
Figure 6: IgH clonality proﬁles from the PCFCL skin biopsy (2006) and the DLBCL gastric biopsy (2009). GeneScan results obtained using
the BIOMED2: (a) FR1 and FR3 and (b) FR2 VH-JH tubes (peaks in blue: patient and control DNA, peaks in red: TAMRA molecular weight
marker). The same 328 base pair and 258 base pair monoclonal product is detected in both the skin and gastric biopsies, after FR1 (a) and
FR2 (b) PCR ampliﬁcation, respectively. No PCR product was detected after FR3 ampliﬁcation (a) probably due to somatic hypermutation.
a complete staging investigation was not performed. How-
ever, the clinical history is very suggestive of Crosti
,sl y m -
phoma [5, 6]. In fact, as clearly shown in the WHO/EORTC
classiﬁcation of cutaneous lymphomas, PCFCL has many
distinct features when compared with nodal FLs, as they
are frequently negative for BCL2 and CD10 and only less
than 25% of the cases have a BCL2 rearrangement. Thus,
the most important diagnostic feature in both lesions is
the BCL6+ (as skin marginal lymphomas are frequently
BCL6 negative). Detection of an identical clonal VH-JH
rearrangement in both biopsies (skin and gastric) obtained
at diﬀerent time points and from diﬀerent locations is
compatible with the presence of the same B cell clone
and strongly suggests transformation of the PCFCL into a
DLBCL.
PCFCL can infrequently progress into extracutaneous,
but transformation into DLBCL has been rarely described
[7].
The current case emphasizes that indolent cutaneous
PCFCL can transform into high-grade lymphoma with poor
outcome. An early diagnosis and proper treatment are
essential in the management of PCFCL.Case Reports in Medicine 5
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